Research programme: PPAR gamma agonists - 3SBio

Drug Profile

Research programme: PPAR gamma agonists - 3SBio

Alternative Names: DJ-5

Latest Information Update: 08 Nov 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Shanghai Institute of Materia Medica
  • Developer 3SBio; Shanghai Institute of Materia Medica
  • Class
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Renal failure

Most Recent Events

  • 29 Oct 2013 Preclinical trials in Renal failure in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top